How to Adjust Sample Size for Dropouts and Noncompliance in Clinical Trials

One of the most overlooked yet critical steps in clinical trial planning is adjusting the calculated sample size to account for patient dropouts and noncompliance. These real-world challenges can significantly reduce the effective power of a study, increasing the risk of inconclusive or biased results. Proactively planning for attrition and protocol deviations ensures the integrity and regulatory acceptability of trial outcomes.

This guide walks through the rationale, formulas, and best practices for adjusting sample sizes for expected dropouts and noncompliance, aligned with expectations from regulatory authorities such as the USFDA and CDSCO.

Why Adjust for Dropouts and Noncompliance?

The ideal number of subjects calculated from a power analysis assumes perfect retention and compliance. However, in real trials:

• Participants may withdraw due to side effects, relocation, or personal reasons
• Subjects may not follow the protocol (miss doses, skip visits)
• Data may be incomplete or lost

These issues compromise the **intention-to-treat (ITT)** and **per-protocol (PP)** populations, reducing power and introducing bias. Adjusting for this anticipated loss ensures that the trial meets its original objectives.

Understanding Dropouts vs. Noncompliance

Dropouts

Participants who discontinue the study prematurely and do not provide complete endpoint data. This affects both ITT and PP analyses.

Noncompliance

Subjects who remain in the study but deviate from the treatment protocol. Their inclusion/exclusion may affect only PP analyses.

Step-by-Step: Adjusting the Sample Size

Step 1: Calculate Initial Sample Size

Use standard formulas based on effect size, alpha, power, and variability, assuming 100% compliance and no attrition.

Step 2: Estimate Dropout and Noncompliance Rates

Base your assumptions on:

• Previous trials in similar indications
• Pilot studies or feasibility assessments
• Therapy burden, follow-up duration, and patient population

Typical dropout rates:

• Short-duration trials: 5–10%
• Chronic conditions: 15–25%
• Oncology or long-term follow-up: ≥30%

Step 3: Inflate Sample Size

The adjusted sample size (n_adjusted) can be calculated using:

  nadjusted = n / (1 − d)
  

Where:

• n = Initial sample size per group
• d = Anticipated proportion of dropouts/noncompliant subjects (e.g., 0.15 for 15%)

Example:

Initial sample size = 120 subjects

Expected dropout = 20%

Adjusted sample size = 120 / (1 − 0.20) = 150 subjects

Handling Multiple Attrition Risks

In some studies, dropout and noncompliance are treated separately. A conservative approach is to add buffers sequentially:

  n′ = n / (1 − dropout) × (1 − noncompliance)
  

Example:

Dropout = 15%, Noncompliance = 10%

n′ = n / (0.85 × 0.90) = n / 0.765

→ Inflate by ~30.7%

Regulatory Perspective on Adjustments

Both regulatory agencies and ethics committees expect realistic planning for attrition. Key expectations:

• Justification of dropout and noncompliance estimates
• Impact assessment on statistical power and endpoint interpretation
• Clear documentation in the SAP and clinical protocol
• Plans for patient engagement and retention strategies

Best Practices for Managing Dropout Impact

1. Historical Data: Use dropout rates from comparable studies as a baseline
2. Protocol Design: Reduce patient burden to minimize attrition
3. Patient Engagement: Incorporate reminders, follow-ups, and retention campaigns
4. Monitoring: Track dropout trends throughout the study for early correction
5. Analysis Populations: Plan ITT, PP, and as-treated analysis sets in advance

Example in Practice: Phase 3 Diabetes Trial

• Initial calculated sample: 180 subjects per arm
• Expected dropout: 15%
• Expected noncompliance: 10%
• n_adjusted = 180 / (0.85 × 0.90) = 235 subjects

The team would plan to recruit 470 subjects total to ensure 360 compliant completers for final analysis.

Tools and Resources

• Sample size calculators with dropout adjustment modules (e.g., G*Power, nQuery)
• Statistical programming in R (e.g., pwr and epiDisplay packages)
• Validation of calculations through pharmaceutical validation processes

Common Mistakes to Avoid

• Using generic dropout rates without context
• Failing to document adjustments in SAP
• Over-recruiting without power recalculation
• Ignoring compliance monitoring plans
• Assuming retention efforts alone will suffice

Conclusion: Proactive Adjustment Ensures Trial Integrity

Failing to account for dropouts and noncompliance can jeopardize an otherwise sound clinical trial. Adjusting the sample size with realistic estimates helps maintain statistical power and aligns with ethical and regulatory expectations. This essential step should be incorporated early during the SAP and protocol development phases, ideally with involvement from a biostatistics and quality assurance team.

Explore More:

• Stability testing protocols
• Pharma SOP checklist
• GMP documentation

“Comparative Analysis of Intention-to-Treat and Per-Protocol Populations”

Introduction

In the world of clinical trials and pharmaceutical research, understanding and analyzing the intention-to-treat (ITT) and per-protocol (PP) populations is of paramount importance. The way these two groups are interpreted can significantly impact the results of a study and, consequently, the development and approval of new medications or treatments. In this tutorial, we will delve into the differences between ITT and PP populations and how to analyze them effectively.

Understanding Intention-to-Treat (ITT) Population

The Intention-to-Treat population includes all participants as initially allocated after randomization. ITT analysis maintains the benefits of randomization: it minimizes bias by including all participants, regardless of whether they withdrew, deviated from the protocol, or even if they were non-compliant with the treatment plan. This approach is considered more conservative as it provides a ‘real-world’ view of a treatment’s effectiveness.

While analyzing the ITT population, it is necessary to handle missing data carefully. Several methods like last observation carried forward (LOCF), multiple imputations, etc., are used to estimate the missing values. It is also crucial to understand the potential reasons for dropouts or deviations, which may reveal important insights about the treatment under study.

Understanding Per-Protocol (PP) Population

The Per-Protocol population, on the other hand, includes only those participants who completed the study as per the original protocol without any protocol violations. The PP analysis provides a measure of the best possible outcome of a treatment under ideal circumstances.

While analyzing the PP population, one must be cautious as this approach is prone to bias, especially if the protocol deviations or dropouts are related to the treatment’s outcome. Unlike the ITT population, the PP population does not provide a ‘real-world’ view but rather an ‘ideal-world’ view of a treatment’s effectiveness.

Why Is It Important to Analyze Both ITT and PP Populations?

Both ITT and PP analyses are important as they provide different perspectives on the treatment’s effectiveness. While ITT analysis provides a more realistic view of the treatment’s effectiveness in a real-world setting, PP analysis provides a view of the treatment’s effectiveness under ideal conditions.

Moreover, both analyses are considered by regulatory authorities like the CDSCO during the approval process. Therefore, a thorough understanding of both ITT and PP populations is essential for researchers, statisticians, and anyone involved in clinical trials.

Understanding the Role of GMP and Regulatory Documentation in Clinical Studies

Good Manufacturing Practices (GMP) and regulatory documentation have a significant role in clinical studies. GMP ensures the quality of pharmaceutical products through a quality system including the GMP manufacturing process and the GMP audit process. On the other hand, regulatory documentation such as the Pharma regulatory documentation ensures compliance with the regulations and guidelines set by regulatory authorities.

Role of Stability Testing and Validation in Clinical Studies

Stability testing and validation are equally important in clinical studies. Pharmaceutical stability testing and Stability studies in pharmaceuticals ensure the drug product’s quality, safety, and efficacy over its shelf-life. Similarly, validation, including HVAC validation in the pharmaceutical industry and Computer system validation in pharma, ensures that the systems and processes used in clinical studies are working as intended.

The Importance of SOPs in Clinical Studies

Standard Operating Procedures (SOPs) play a crucial role in clinical studies. SOPs ensure consistency, efficiency, and quality in the operations. Furthermore, Pharma SOPs and SOP writing in pharma are essential for maintaining compliance with regulatory requirements.

Conclusion

Understanding and analyzing ITT and PP populations in clinical studies require a deep understanding of clinical trial methodology, statistical analysis, and regulatory requirements. By combining this knowledge with best practices in GMP, regulatory documentation, stability testing, validation, and SOPs, you can conduct high-quality clinical studies that contribute to the development and approval of safe and effective medications and treatments.